Usefulness of 2-[18F]-fluoro-2-deoxy- d -glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: A retrospective multicenter study

Arthritis Care and Research

Volumn 66, Issue 1, 2014, Pages 86-96

  Ebbo, Mikael ^a   Grados, Aurélie ^a   Guedj, Eric ^b   Gobert, Delphine ^c   Colavolpe, Cécile ^b   Zaidan, Mohamad ^d   Masseau, Agathe ^e   Bernard, Fanny ^f   Berthelot, Jean Marie ^e   Morel, Nathalie ^g   Lifermann, François ^h   Palat, Sylvain ⁱ   Haroche, Julien ^g   Mariette, Xavier ^j   Godeau, Bertrand ^k   Bernit, Emmanuelle ^a   Costedoat Chalumeau, Nathalie ^g   Papo, Thomas ^c   Hamidou, Mohamed ^e   Harlé, Jean Robert ^a   Schleinitz, Nicolas ^a   more..

^a HÔPITAL DE LA CONCEPTION   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c BICHAT HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HÔTEL DIEU   (France)

^f HÔPITAL NORD   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h Observatoire de Dax   (France)

ⁱ DUPUYTREN UNIVERSITY HOSPITAL   (France)

^j BICÊTRE HOSPITAL   (France)

^k HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN G4; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; TOCILIZUMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PREDNISONE; STEROID;

ADULT; AGED; ARTERY DISEASE; ARTICLE; BRAIN DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; ECHOGRAPHY; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN G4 RELATED DISEASE; INTERMETHOD COMPARISON; KIDNEY DISEASE; LYMPHADENOPATHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REGISTER; RELAPSE; RETROSPECTIVE STUDY; SALIVARY GLAND DISEASE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; WHOLE BODY CT; WHOLE BODY PET; EVALUATION STUDY; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; POSITRON EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY; CLINICAL TRIAL; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STEROIDS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84891072508     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22058     Document Type: Article

References (41)

1. Okazaki K, Uchida K, Koyabu M, Miyoshi H, Takaoka M,. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease. J Gastroenterol 2011; 46: 277-88.
2. Uchida K, Masamune A, Shimosegawa T, Okazaki K,. Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009. Int J Rheumatol 2012; 2012: 358371.
3. Zen Y, Nakanuma Y,. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 2011; 34: 1812-9.
4. Ebbo M, Daniel L, Pavic M, Seve P, Hamidou M, Andres E, et al. IgG4-related systemic disease: features and treatment response in a French cohort. Results of a multicenter registry. Medicine (Baltimore) 2012; 91: 49-56.
5. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25: 1181-92.
6. Maire F, Le Baleur Y, Rebours V, Vullierme MP, Couvelard A, Voitot H, et al. Outcome of patients with type 1 or 2 autoimmune pancreatitis. Am J Gastroenterol 2011; 106: 151-6.
7. Kamisawa T, Egawa N, Inokuma S, Tsuruta K, Okamoto A, Kamata N, et al. Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy. Pancreas 2003; 27: 235-8.
8. Raissian Y, Nasr SH, Larsen CP, Colvin RB, Smyrk TC, Takahashi N, et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol 2011; 22: 1343-52.
9. Ebbo M, Grados A, Bernit E, Vely F, Boucraut J, Harle JR, et al. Pathologies associated with serum IgG4 elevation. Int J Rheumatol 2012; 2012: 602809.
10. Yamamoto M, Tabeya T, Naishiro Y, Yajima H, Ishigami K, Shimizu Y, et al. Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol 2012; 22: 419-25.
11. Morel N, Rigolet A, Schleinitz N, Garnier A, Costedoat-Chalumeau N,. Bilateral enlargement of the lacrimal glands from IgG4-related systemic disease [letter]. Ann Intern Med 2012; 156: 669-70.
12. Shimizu Y, Yamamoto M, Naishiro Y, Sudoh G, Ishigami K, Yajima H, et al. Necessity of early intervention for IgG4-related disease: delayed treatment induces fibrosis progression. Rheumatology (Oxford) 2013; 52: 679-83.
13. Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-7.
14. Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czako L, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2012. E-pub ahead of print.
15. Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, Vucinic-Mihailovic V, Artiko V, Saranovic D, et al. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med 2012; 53: 1543-9.
16. Treglia G, Mattoli MV, Leccisotti L, Ferraccioli G, Giordano A,. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin Rheumatol 2011; 30: 1265-75.
17. Sato M, Okumura T, Shioyama Y, Imura J,. Extrapancreatic F-18 FDG accumulation in autoimmune pancreatitis. Ann Nucl Med 2008; 22: 215-9.
18. Nakajo M, Jinnouchi S, Fukukura Y, Tanabe H, Tateno R, Nakajo M,. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. Eur J Nucl Med Mol Imaging 2007; 34: 2088-95.
19. Matsubayashi H, Furukawa H, Maeda A, Matsunaga K, Kanemoto H, Uesaka K, et al. Usefulness of positron emission tomography in the evaluation of distribution and activity of systemic lesions associated with autoimmune pancreatitis. Pancreatology 2009; 9: 694-9.
20. Ozaki Y, Oguchi K, Hamano H, Arakura N, Muraki T, Kiyosawa K, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol 2008; 43: 144-51.
21. Suga K, Kawakami Y, Hiyama A, Hori K, Takeuchi M,. F-18 FDG PET-CT findings in Mikulicz disease and systemic involvement of IgG4-related lesions. Clin Nucl Med 2009; 34: 164-7.
22. Nguyen VX, De Petris G, Nguyen BD,. Usefulness of PET/CT imaging in systemic IgG4-related sclerosing disease: a report of three cases. JOP 2011; 12: 297-305.
23. Nakajo M, Jinnouchi S, Noguchi M, Uozumi K, Tanabe H, Tateno R, et al. FDG PET and PET/CT monitoring of autoimmune pancreatitis associated with extrapancreatic autoimmune disease. Clin Nucl Med 2007; 32: 282-5.
24. Nakatani K, Nakamoto Y, Togashi K,. Utility of FDG PET/CT in IgG4-related systemic disease. Clin Radiol 2012; 67: 297-305.
25. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012; 22: 21-30.
26. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging. Version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200.
27. Kamisawa T, Okazaki K, Kawa S, Shimosegawa T, Tanaka M,. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 2010; 45: 471-7.
28. Tomiyama T, Uchida K, Matsushita M, Ikeura T, Fukui T, Takaoka M, et al. Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis. J Gastroenterol 2011; 46: 696-704.
29. Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2012. E-pub ahead of print.
30. Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH,. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 2012; 91: 57-66.
31. Tabata T, Kamisawa T, Takuma K, Egawa N, Setoguchi K, Tsuruta K, et al. Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. Intern Med 2011; 50: 69-75.
32. Saegusa H, Momose M, Kawa S, Hamano H, Ochi Y, Takayama M, et al. Hilar and pancreatic gallium-67 accumulation is characteristic feature of autoimmune pancreatitis. Pancreas 2003; 27: 20-5.
33. Vaglio A, Versari A, Fraternali A, Ferrozzi F, Salvarani C, Buzio C,. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis. Arthritis Rheum 2005; 53: 122-5.
34. Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68: 1310-5.
35. Yamamoto M, Takahashi H, Ishigami K, Yajima H, Shimizu Y, Tabeya T, et al. Relapse patterns in IgG4-related disease [letter]. Ann Rheum Dis 2012; 71: 1755.
36. Detlefsen S, Zamboni G, Frulloni L, Feyerabend B, Braun F, Gerke O, et al. Clinical features and relapse rates after surgery in type 1 autoimmune pancreatitis differ from type 2: a study of 114 surgically treated European patients. Pancreatology 2012; 12: 276-83.
37. Nishina N, Kaneko Y, Kuwana M, Hanaoka H, Kameda H, Mikami S, et al. IgG4-related disease without overexpression of IgG4: pathogenesis implications. Case Rep Rheumatol 2012; 2012: 754935.
38. Carruthers MN, Stone JH, Deshpande V, Khosroshahi A,. Development of an IgG4-RD responder index. Int J Rheumatol 2012; 2012: 259408.
39. Vaglio A, Greco P, Versari A, Filice A, Cobelli R, Manenti L, et al. Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent "scar"? A study using 18F- fluorodeoxyglucose positron emission tomography. Clin Exp Rheumatol 2005; 23: 231-4.
40. Shapiro KA, Bove RM, Volpicelli ER, Mallery RM, Stone JH,. Relapsing course of immunoglobulin G4-related pachymeningitis. Neurology 2012; 79: 604-6.
41. Yamamoto M, Takahashi H, Tabeya T, Suzuki C, Naishiro Y, Ishigami K, et al. Risk of malignancies in IgG4-related disease. Mod Rheumatol 2012; 22: 414-8.